Italfarmaco   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Milan Italy (1938)

Organization Overview

First Clinical Trial
2003
NCT00951574
First Marketed Drug
2018
riluzole (rilutek)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Italfarmaco | Italfarmaco S.A | Italfarmaco S.p.A. | ITALFARMACO SPA

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acromegaly (Phase 2)

Arthritis (Phase 2)

Arthritis, Juvenile (Phase 2)

Atrophy (Phase 3)

Crohn Disease (Phase 2)

Hodgkin Disease (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Multiple Myeloma (Phase 2)

Muscular Dystrophies (Phase 3)

Muscular Dystrophy, Duchenne (Phase 3)

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Polycythemia (Phase 2)

Polycythemia Vera (Phase 2)

Thromboembolism (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 25
  • # of Trial APIs: 12